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ERp57Myelin oligodendrocyte glycoprotein (MOG) is a type I integral membrane glycoprotein that localizes to
myelin sheaths in the central nervous system. MOG has important implications in multiple sclerosis, as
pathogenic anti-MOG antibodies have been detected in the sera of multiple sclerosis patients. As a membrane
protein, MOG achieves its native structure in the endoplasmic reticulum where its folding is expected to be
controlled by endoplasmic reticulum chaperones. Calnexin, calreticulin, and ERp57 are essential components
of the endoplasmic reticulum quality control where they assist in the proper folding of newly synthesized
glycoproteins. In this study, we show that expression of MOG is not affected by the absence of the
endoplasmic reticulum quality control proteins calnexin, calreticulin, or ERp57. We also show that calnexin
forms complexes with MOG and these interactions might be glycan-independent. Importantly, we show that
cell surface targeting of MOG is not disrupted in the absence of the endoplasmic reticulum chaperones. This
article is part of a special issue entitled: 11th European Symposium on Calcium.opean Symposium on Calcium.
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Myelin is the multilamellar sheath surrounding the large axons in
the peripheral and central nervous systems and is essential for fast
signal transmission. Myelin formation depends on myelin proteins.
One of the minor (0.05%) components of the central nervous system
(CNS) myelin is myelin oligodendrocyte glycoprotein (MOG).1 This
protein is expressed within the outermost lamellae of the myelin
sheath, cell body, and processes of oligodendrocytes [1]. MOG is a 28-
kDa cell surface glycoprotein with a single N-glycosylation site at N31
and one disulﬁde bond formed between C24 and C98 in the im-
munoglobulin (Ig)-like extracellular domain [2]. The amino acid
sequence of MOG is highly conserved among animal species, and the
crystal structure of its extracellular domain has demonstrated that it
forms head-to-tail dimer in solution, which would suggest dimeriza-
tion and potential homophilic (self-association) interactions [2]. MOG
plays an important role in the pathology of multiple sclerosis, a
chronic inﬂammatory disease of the CNS by inﬂuencing multiplesclerosis susceptibility as a primary target for autoimmune response
[3]. Anti-MOG antibodies have been found in the sera of patients with
multiple sclerosis, and their presence is directly associated with
myelin damage. Previous studies suggest that encephalitogenic
antibodies recognize conformation-dependent epitopes of MOG [4].
As an integral membrane protein, MOG is synthesized in the
endoplasmic reticulum (ER) and subsequently targeted to the surface
of oligodendrocytes. These eventsmust be closelymonitored by the ER
quality control system that consists of molecular chaperones and
folding enzymes. Calnexin and calreticulin, two ER lectin chaperones,
play a crucial role in the quality control process. Calnexin and
calreticulin are both calcium-binding chaperones in the ER [8,17,21].
Calreticulin plays especially important role in cellular calcium
homeostasis as it is responsible for buffering of over 50% of the ER
calcium and it affects the function of the store operated calcium inﬂux
[8]. The twoER lectin-like calcium-binding chaperones each consists of
a globular domain, which contains a glycan-binding site and an
extended, proline-rich domain (P-arm) that is known to associatewith
ERp57, an oxidoreductase that belongs to the protein disulﬁde
isomerse (PDI) family [5,6]. ERp57 catalyzes formation and isomeri-
zation of disulﬁde bonds in newly synthesized glycoprotein (often
calnexin and calreticulin substrates) within the ER. Despite MOG
playing a critical role in the pathology of multiple sclerosis, the role of
ER associated chaperones and folding enzymes in the biology of MOG
and, consequently in the pathology of multiple sclerosis, is not known.
Here we identiﬁed calnexin as an ER molecular chaperone for MOG
and examined the role of ER quality control in the MOG expression,
trafﬁcking, and unfolded protein response (UPR). This work provides
Fig. 1. Interaction between calnexin and MOG. Cell lysates were collected from wild-
type (wt) cells stably expressing MOG green ﬂuorescent protein (GFP) followed by
addition of the goat anti-GFP antibodies as indicated in the ﬁgure and as described
under “Experimental procedures”. Proteins were separated by SDS-PAGE followed by
Western blot analysis with anti-calnexin (anti-CNX) antibodies. A representative
Western blot of 3 independent experiments is shown. Cells were cultured in the
presence of 1 mM castanospermine for 16 h followed by immunoprecipitation and
Western blot analysis to test for a glycan-dependent interaction between calnexin and
MOG–GFP. Calnexin-deﬁcient cells (cnx−/−) stably expressing MOG–GFP were used as
a negative control. The arrow indicates the location of calnexin (CNX) and the asterisk
mark unspeciﬁc bands.
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new potential players, which may contribute to folding and confor-
mation of MOG and therefore to its encephalitogenic properties.
2. Experimental procedures
2.1. Vector DNA
The full-length cDNAs encoding mouse MOG were cloned into
pEGFP-N1 vector to create vectors encoding MOG with green ﬂuo-
rescent protein (GFP) at its carboxyl termini MOG–GFP. The following
DNA primers containing an attB recombination site (Gateway Cloning,
Invitrogen) were used: forward primer 5′-GGGGAC AAG TTT GTA CAA
AAA AGC AGG CTA TAC CAT GAT GGC CTG TTT GTG GAG CTT CTC-3′
reverse primer 5′-GGG GAC CAC TTT GTA CAA GAA AGC TGG GTT TTA
CTT GTA CAG CTC GTC CAT GCC-3′. First the PCR products were cloned
into the pDONR vector (Invitrogen) using LR Clonase Enzyme
(Invitrogen). Next, the recombination reaction was carried out using
BP Clonase Enzyme Mix (Invitrogen) with the gene of interest, the
ubiquitously expressed promoter, EF1α (cellular polypeptide chain
elongation factor 1 alpha), and a destination vector 2K7bsd containing
a blasticidin resistance gene that allows the easy selection of
transfected cells [7]. Virus isolation and transduction were carried
out as described previously [7].
2.2. Cell culture, cell lines, and immunoﬂuorescence
Wild-type (K41) and calreticulin-deﬁcient (K42) mouse embryonic
ﬁbroblasts were described previously [8]. ERp57-deﬁcient mouse
embryonic ﬁbroblasts were isolated from ERp57−/− embryos and
immortalized [8,9]. Wild-type and calnexin-deﬁcient mouse ﬁbroblasts
were isolated from newborn mice and immortalized [10]. Lentiviral
expression constructs encoding MOG–GFP were used to create wild-
type, calnexin-deﬁcient (cnx−/−), calreticulin-deﬁcient (crt−/−) and
ERp57−/−-deﬁcient cell lines stably expressing recombinantMOG–GFP.
Cells were cultured in the presence of 7 μg/ml blasticidine for 14 days.
Expression of MOG–GFP protein was monitored by Western blot
analysis using anti-GFP antibodies or by immunoﬂuorescence, co-
staining with ER marker TexasRed Concanavalin A conjugate using
confocal microscopy. For immunoﬂuorescence, cells expressing MOG–
GFP were grown for 24 h after seeding in culture media and ﬁxed in 4%
paraformaldehyde for 12 min [10]. Images were collected by spinning-
diskmicroscopy (Guelph, Canada) set up on anOlympus IX-81 inverted
stand (Markham, Canada). Images were acquired through a 60×
objective (N.A. 1.42) with an Electron Multiplying Charge Coupled
Device (EMCCD) camera (Hamamatsu, Japan).
2.3. Western blot analysis and immunoprecipitation
Brains and cerebellum from mice were isolated, crushed in liquid
nitrogen, and lysed inRIPAbuffer containing150 mMNaCl, 50 mMTris–
HCl, pH 7.4, 0.5% Nonidet P-40, 1% deoxycholate, 0.1% sodium dodecyl
sulphate, andprotease inhibitors for 15 minon ice [11]. ForWesternblot
analysis, cells expressingMOG–GFP were lysed on ice in RIPA buffer for
15 min [10]. The following antibodies were used: goat anti-GFP
1:10,000, rabbit anti-MOG 1:300, rabbit anti-calnexin (Stressgene),
rabbit anti-calreticulin 1:300, rabbit anti-ERp57 1:1000, and rabbit anti-
glyceraldehyde dehyrodenase (GAPDH) 1:1000.
For immunoprecipitation, cells were grown to 80–90% conﬂuency
followed by the addition of 500 μl/10 cmdishof A lysis buffer containing
50 mMHepes, pH 7.4, 200 mMNaCl, 2% CHAPS and protease inhibitors
[12]. Sampleswere incubatedon ice for 30 minand then spunat11,600g
for 15 min to remove insoluble material. Supernatant was pre-cleared
with a 1/15th of 10% protein A/G Sepharose bead suspension in an HBS
buffer containing 50 mMHEPES, pH 7.4, and 200 mMNaCl. Beads were
centrifuged followed by addition of 2 μl of an appropriate antibody. Thesamples were incubated overnight at 4 °C with rotation followed by
addition of 100 μl of 10% protein A/G Sepharose in HBS buffer and
incubated for an additional 4 h. Beadswere centrifuged, washed 3 times
withHBS containing 1% CHAPS, one timewithHBS, followed byaddition
of 30 μl of SDS-PAGE sample buffer [13]. Proteins were separated
by SDS-PAGE (10% acrylamide). Cells were also culture with 1 mM
castanospermine for 16 h.
2.4. Endoglycosidase digestions
Cellular proteins were extractedwith RIPA buffer and 20 μg of total
protein was incubated with EndoH or PNGaseF at 37 °C for 3 h
according to the manufacturer's protocols. Digested and undigested
samples were separated by SDS-PAGE (10% acrylamide) followed by
Western blot analysis with rabbit anti-GFP antibodies at 1:10,000.
2.5. Analysis of unfolded protein response (UPR)
The UPR was measured using the luciferase reporter gene assay
[10]. In brief, wild-type, cnx−/−, ERp57−/− and crt−/−cells stably
expressing MOG–GFP were transfected with pRL-XFL vector encoding
Renilla luciferase and Fireﬂy luciferase reporter genes [10,14]. Brieﬂy,
1 μg of DNA was transfected using Effectene (Qiagen). Cells were
treated with 1 μM thapsigargin for 16 h, lysed, diluted, and assayed
with the Dual-Luciferase Assay Kit (Promega) using a luminometer
(Berthold-Lumat LB 9501). Relative light units (RLUs) were normal-
ized to internal control. Average±standard deviation (SD) (n=3).
3. Results and discussion
3.1. Calnexin interacts with MOG
In eukaryotic cells, membrane and secreted proteins fold and
achieve their native structures in the ER. Calnexin is one of the ER
associated molecular chaperones and, together with oxidoreductase
ERp57, assists many glycoproteins to achieve their ﬁnal conﬁrmation
[15]. MOG is a glycoprotein with a single N-glycosylation site and a
single disulﬁde bond, which makes it a potential candidate for
calnexin and ERp57 substrate. We asked whether calnexin and ERp57
form complexes with the newly synthesized MOG. Stable expression
of MOG–GFP in wild-type cells was followed by immunoprecipitation
with anti-GFP antibodies and Western blot analysis with either anti-
ERp57 or anti-calnexin antibodies. Fig. 1 shows that calnexin formed
complexes with MOG indicating that calnexin may play a role in MOG
folding. Attempts to immunoprecipitate MOG with ERp57 failed
indicating that ERp57may not interact directly withMOG. To examine
Fig. 2. Expression of MOG in wild-type and chaperone-deﬁcient cells. A–B. Wild-type
(wt), calnexin-deﬁcient (cnx−/−), ERp57-deﬁcient (ERp57−/−) and calreticulin-
deﬁcient (crt−/−) cells were transfected with expression vectors encoding MOG–GFP
as described under “Experimental procedures”. Western blot analysis was carried out
with antibodies as indicated in the ﬁgure 20 μg of total protein was loaded on the gel;
calreticulin (CRT), calnexin (CNX), green ﬂuorescent protein (GFP), and glyceraldehyde
dehydrogenase (GAPDH). C. Brain and cerebellum samples from wild-type (wt) and
calnexin-deﬁcient (cnx−/−) mice were collected with RIPA buffer followed by Western
blot analysis with anti-MOG antibodies, 30 μg of protein was loaded on the gel. The
asterisk indicates the location of MOG.
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treated cells stably expressing MOG–GFP with castanospermine. This
glycosidase inhibitor prevents removal of ﬁrst glucose residue and
consequently processing of the oligosaccharide chain and therefore
the formation of monoglucosylated substrate that would be recog-
nized by calnexin [16]. Fig. 1 shows that calnexin–MOG complexes
formed even in the presence of castanospermine, an inhibitor of
glucosidase I/II indicating this interaction was sugar-independent.
This further supports the “dual-binding” model for glycan-dependent
and glycan-independent interaction between calnexin and its
substrates what has been proposed previously by Williams et al. [17].
3.2. Expression of MOG in the absence of ER chaperones
Next we examined if the expression of MOG is affected by the
absence of quality control chaperones. Wild-type, cnx−/−, crt−/− and
ERp57−/− cells were transfected with an expression vector encoding
MOG–GFP followed by Western blot analysis with anti-GFP and anti-
MOG antibodies (Fig. 2). Fig. 2A and B shows that expression of MOG
was at comparable levels in chaperone-deﬁcient and wild-type cells,
indicating that it was not affected by the absence of the ER
chaperones. Calnexin-deﬁcient mice are viable [18] and therefore
permit analysis of MOG expression in mouse tissue. Fig. 2C shows that
similar to the analysis of cultured cells expressing MOG–GFP,
endogenous expression of MOG in wild-type and cnx−/− brain and
cerebellum of the mouse was not altered. We concluded that the
absence of ER chaperones calnexin, calreticulin, and folding enzyme
ERp57 did not have any effect on the expression of MOG. It is
conceivable that other ER chaperone such as GRP78/BiP and/or GRP94
[21] may compensate for the absence of calnexin or calreticulin and
assist in MOG folding. Furthermore, there are several oxidoreductases
associated with the ER membrane such as PDI, ERp72, ERp44, and
others [21], and they, in turn, may compensate for the absence of
ERp57 in the MOG disulﬁde bond formation and isomerization.
3.3. Plasma membrane localization of MOG in cells deﬁcient in ER
chaperones
Formyelinproteins to perform their function, theyhave tobe localized
to the plasma membrane of cells forming myelin sheaths. To test if MOG
cell surface targeting was affected in the absence of ER chaperone, we
expressed MOG–GFP in chaperone-deﬁcient cells (cnx−/−, crt−/− and
ERp57−/−) and examined the localization of MOG–GFP by confocal
microscopy. Fig. 3 shows that MOGwas localized primarily to the plasma
membrane in the absence of calnexin, calreticulin, or ERp57. We did not
observe signiﬁcant co-localization of MOG with Concanavalin A, which
was used as an ER marker. The weak intracellular GFP signal likely
corresponds to ER localized MOG–GFP that is newly synthesized.
MOG contains a single N-linked glycosylation site at N31. This
post-translational modiﬁcation has been identiﬁed to be important
during antibody recognition of MOG upon experimental autoimmune
encephalomyelitis [19]. Calnexin, calreticulin, and ERp57 play a key
role in the folding of glycosylated proteins [20,21]. Properly folded,
mature, plasma membrane localized MOG contains a single N-
glycosylation site within its extracellular domain, and the presence
of mature sugar indicates plasma membrane localization. We asked
whether the absence of ER quality control chaperones affects the
glycosylation state of myelin proteins. The state of maturity of a
speciﬁc glycoprotein can be deduced from its sensitivity to hydrolysis
by speciﬁc glycosidases (endoglycosidase H [EndoH] or N-glycosidase
F [PNGaseF]); digestion with EndoH removes high mannose, ER
localized, N-linked carbohydrates; whereas digestion with PNGaseF
removes both high mannose and complexed carbohydrates. A fully
matured glycoprotein will bemodiﬁedwith complex oligosaccharides
making it resistant to cleavage by EndoH but not PNGaseF [22].
MOG–GFP expressed in wild-type and chaperone-deﬁcient cells washighly sensitive to PNGaseF digestion indicating the presence of
complex, mature carbohydrate (Fig. 4A). In contrast, MOG expressed
in all the cell lines was resistant to EndoH digestion (Fig. 4A). These
results indicate that the absence of an essential ER chaperone did not
result in changes to glycosylation of MOG. Furthermore, they support
cell surface localization of MOG as revealed by confocal analysis
(Fig. 3). Combined, confocal analysis and glycosidases sensitivity
studies demonstrate that the absence of calnexin, calreticulin, or
ERp57 did not interfere with the cell surface trafﬁcking of MOG–GFP.
This indicates that ER quality control components (calnexin,
Fig. 3. Expression and cell surface targeting of MOG–GFP in wild-type and chaperone-deﬁcient cells. Confocal images of cell surface expression of MOG–GFP (green) in calnexin-
deﬁcient (cnx−/−), ERp57-deﬁcient (ERp57−/−), calreticulin-deﬁcient (crt−/−), and wild-type (wt) cells. Concanavalin-A (red) staining was used as an ERmarker. Scale bar=17 μm.
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targeting of MOG.
A single disulﬁde bond is found in the extracellular domain ofMOG
between C24 and C98, and the disulﬁde bond on MOGmay be essential
for its function as it is for myelin protein zero that contains single
disulﬁde bond in its Ig-like extracellular domain just like MOG [23].
ERp57 is the oxidoreductase that assists many calnexin substrates in
disulﬁde bond formation and/or isomerization [15]. Therefore, we
used SDS-PAGE under reducing and non-reducing conditions to test
whether disulphide bond formation in MOG was affected in the
absence of the oxidoreductase ERp57. As expected, in the wild-type
cells expression of MOG–GFP, the mobility of the protein in SDS-PAGE
was affected under reducing and non-reducing conditions (Fig. 4B,
wt) indicating that MOG–GFP expressed in wild-type cells formed adisulﬁde bond. Surprisingly, the SDS-PAGE mobility of MOG–GFP
expressed in ERp57-deﬁcient cells was also sensitive to a reduced
and non-reduced environment, indicating that MOG formed a
disulﬁde bond even in the absence of ERp57 oxidoreductase
(Fig. 4B, ERp57−/−). This was a surprising result as disulﬁde bond
formation in the ER of calnexin substrates is catalyzed by ERp57 [15].
MOG, like other myelin proteins, contains an Ig domain, and the
disulﬁde bond is an important posttranslational modiﬁcation of the
protein affecting its stability and function [23,24]. ERp57 has been
extensively studied from the perspective of the folding of MHC I
molecules (that belong to the same Ig family asMOG) [6]. Our ﬁndings
indicate that the absence of the ERp57 oxidoreductase did not result
in the failure to form a disulﬁde bond in the extracellular domain of
MOG suggesting that disulﬁde bond formation occurs in the absence
Fig. 4. Glycosylation and disulﬁde bond formation in MOG expressed in wild-type and
chaperone-deﬁcient cells. A. A representative Western blot of endoglycosidases
digestion of MOG–GFP expressed in wild-type (wt) and chaperone-deﬁcient cell
lines: calnexin-deﬁcient (cnx−/−), ERp57-deﬁcient (ERp57−/−), and calreticulin-
deﬁcient (crt−/−). First lane represents untreated sample; PNGaseF, N-glycosidase-F
digestion; EndoH, endoglycosidase H digestion. Blots were probed with andante-GFP
antibodies. The arrows show the endoglycosidases sensitive fraction of the protein.
B. Western blot analysis of MOG–GFP expressed in wild-type (wt) or ERp57-deﬁcient
(ERp57−/−) cells under reducing (+β ME) or non-reducing (−β ME) conditions. The












































Fig. 5. Unfolded protein response in chaperone-deﬁcient cells expressing MOG. Wild-
type (wt), cnx−/−, ERp57−/−; and wild-type, cnx−/−, ERp57−/− stably expressingMOG–
GFP were transfected with pRL-XFL vector encoding Renilla luciferase and ﬁreﬂy
luciferase reporter genes as described previously [10,14]. As a positive control, cells
were treated with 1 μM thapsigargin (TG) for 16 h. Cell extracts were collected and
assayed for luciferase activity with the Dual-Luciferase Assay Kit (Promega) using a
luminometer (Berthold-Lumat LB 9501) [10,14]. Relative light units (RLU) were
normalized to internal control. Average values±standard deviation (SD) (n=3).
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PDI family of oxidoreductases compensate for the absence of ERp57
and promote disulﬁde bond formation for this calnexin substrate.
3.4. The UPR in the absence of ER chaperones
Accumulation of misfolded proteins in the ER might result in the
activation of the UPR and may lead to pathogenic consequences [25].
To test if expression of MOG in cells deﬁcient in ER chaperones
activated the UPR, we used a dual luciferase system to measure the
UPR [10,14]. Thapsigargin induces a high level of ER stress and was
used in these experiments as a positive control (Fig. 5). Fig. 5 shows
that expression of MOG in the absence of ER chaperones did not result
in activation of the UPR and conﬁrmed that MOG was not accu-
mulating in the ER in the absence of ER quality control chaperones
calnexin, calreticulin, or ERp57. Although indirectly, these results
support our conclusions that MOG–GFP was efﬁciently target to cell
surface in the absence of calnexin, calreticulin, or ERp57. High-level
ER stress and induction of UPR signaling can lead to apoptosis [26] and
pathological phenotypes. Interestingly, ER stress-related pathways
are activated when EAE antibodies bind to MOG [27] and may have a
protective effect against EAE-induced oligodendrocyte death and
demyelination [28]. The ER stress may, therefore, have both beneﬁcialand detrimental effects on immune-mediated demyelination and,
consequently, on the pathology of multiple sclerosis. We show here
that MOG is not accumulated in the ER in the absence of ER-associated
chaperones and it does not activate ER stress. A more detailed analysis
and understanding of the biology of MOG, ER chaperones, and
ER stress could be critical when considering potential therapeutic
approaches for myelin disorders.
Multiple sclerosis is a chronic inﬂammatory disease of the CNS
often affecting young adults. The etiology of the disease is still largely
unknown, but there is strong evidence that this is an autoimmune
multifactorial disease. Despite many efforts to identify genes involved
in disease susceptibility, only a few genes have been identiﬁed to be
involved. Although the MOG gene has been identiﬁed in a genome
screen of multiple sclerosis families as associated with the disease
[29], the association between MOG gene polymorphisms and
susceptibility to multiple sclerosis is still inconsistent and inconclu-
sive [29]. Polymorphisms or mutations in the MOG gene may
contribute to the development and progression of multiple sclerosis
by diversemechanisms [29] including loss of function thatmay lead to
myelin instability and increased sensitivity to immune attack.
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